Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Aduro Clean Technologies erreicht wichtigen Meilenstein: Übergang seiner NGP-Pilotanlage in Phase der Betriebskampagne

View original at globenewswire.com
Aduro Clean Technologies erreicht wichtigen Meilenstein: Übergang seiner NGP-Pilotanlage in Phase der Betriebskampagne LONDON, Ontario, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • This milestone is the result of disciplined execution by our engineering, operations, and project teams. With the NGP pilot plant now in structured test operation, it becomes an important asset paving our path to commercialization and deepening collaboration with partners

    80% confidence

  • After commissioning, our main focus is on operating the integrated system and the insights gained from it. The NGP pilot plant expands on investigations conducted in the R2 flow reactor and enables us to test mixed plastic waste samples from customer programs and other real-world sources under longer run times and more integrated operating conditions

    80% confidence

  • Aduro is well positioned to generate relevant operational and environmental performance data that will support and advance its commercialization program

    80% confidence

  • The NGP pilot plant is operating as expected and initial campaigns align with planned test series

    80% confidence

  • The FOAK plant site has been selected and ongoing activities in London will flow directly into design and integration planning, strengthening the company's readiness to execute the next phase of scale-up

    80% confidence

  • These campaigns serve to refine operating parameters for optimal yield and consistent performance with varying feedstocks while simultaneously validating design assumptions for the industrial FOAK plant

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com